Sirolimus-eluting stents for in-stent restenosis demonstrated a 99% procedural success rate, with recurrent ISR in 11.8% and long-term MACE in 12.8% of patients at a median 15.1 months.
Observational (n=100)
Does treatment with sirolimus-eluting stents improve clinical and angiographic outcomes in patients with in-stent restenosis?
Sirolimus-eluting stents demonstrate feasibility, safety, and effectiveness for treating in-stent restenosis, with acceptable long-term MACE and recurrence rates.
OBJECTIVES: The aims of this study were to assess (i) the feasibility, safety and efficacy of sirolimus-eluting stents (SESs) in treating in-stent restenosis (ISR), (ii) the risk factors for recurrent ISR, and (iii) the long-term major adverse cardiac events (MACE). METHODS: Between May 2002 and April 2004, 100 consecutive patients with evidence of myocardial ischaemia and 112 ISRs in native coronary arteries were treated using SESs. We evaluated the rate of procedural and clinical success, the incidence of in-hospital and long-term MACE, the recurrence rate of ISR after 6-8 months, and the risk factors for recurrent ISR and follow-up MACE. RESULTS: Forty-five percent of the lesions were directly stented. After stent implantation, the minimal lumen diameter increased from 0.51 +/- 0.32 to 2.50 +/- 0.32 mm in the stents and to 2.30 +/- 0.35 mm in the lesions (acute gain 1.99 +/- 0.37 mm). The procedural success rate was 99%. The clinical success rate was 88%. MACE occurred in 2.0% of patients during hospitalisation and in 12.8% after a median follow-up of 15.1 months (interquartile range 8.4-19.7). The recurrence rate of ISR was 11.8% after a median follow-up of 7.7 months (interquartile range 7.4-8.4). The risk for recurrent ISR was significantly higher in patients with diabetes or hypertension, in those aged more than 65 years and in female patients, as well as in the lesions with a small minimal lumen diameter. Three-vessel disease and age were risk factors for MACE. CONCLUSIONS: This study confirms the feasibility, safety and effectiveness of using SESs to treat ISR, and identifies a risk profile for recurrent ISR and MACE.
Brambilla et al. (Sat,) conducted a observational in In-stent restenosis (n=100). Sirolimus-eluting stents (SESs) was evaluated on Long-term major adverse cardiac events (MACE). Sirolimus-eluting stents for in-stent restenosis demonstrated a 99% procedural success rate, with recurrent ISR in 11.8% and long-term MACE in 12.8% of patients at a median 15.1 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: